Akero Therapeutics soars more than 100% in early trading on early 'fatty liver' trial data - San Francisco Business Times

📆 13/09/2022 20:45:00
📰 SFBusinessTimes

⏱ Reading Time:
17 sec. here
2 min. at publisher
📊 Quality Score:
News: 10%
Publisher: 68%

France Nouvelles Nouvelles

France Dernières Nouvelles,France Actualités

Results from a clinical trial of its drug in the 'fatty liver' disease NASH sent $AKRO's stock soaring

Encouraging data on a South San Francisco company's drug targeting the fatty liver disease NASH pushed its stock 120% higher in early trading Tuesday.

Most side effects — diarrhea, nausea, increased appetite and frequent bowel movements — were transient, the company said. EFX, formerly known as AKR-001, is Akero's lead product candidate, designed not only to reduce liver fat and inflammation but to reduce fibrosis. It is injected once a week into a layer of skin.

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Écrire un Commentaire

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

Warriors, 49ers and Giants land on Forbes' 2022 most valuable teams list - San Francisco Business TimesThe NFL has made a run for the top spots this year, bumping the MLB and the NBA out of the top three.
La source: SFBusinessTimes - 🏆 78. / 68 Lire la suite »

Universal Paragon Corp. proposes Project Axon at Sierra Point in Brisbane - San Francisco Business TimesThe proposed hotel near the Brisbane Marina is envisioned with over 600 rooms and an outdoor wedding chapel. An adjacent life sciences building will rise 11 stories.
La source: SFBusinessTimes - 🏆 78. / 68 Lire la suite »